10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2009 | |||
Statement Of Income Alternative | |||
Period Ending Dec 31, 2009 10-K (Filed: Mar 1, 2010) | |||
| (In Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2009 | Dec 31, 2008 | Dec 31, 2007 | |
| Revenues: | |||
| Product sales | $ 6,469,311 | 5,084,796 | 3,733,109 |
| Royalty revenues | 491,818 | 218,180 | 468,155 |
| Contract and other revenues | 50,254 | 32,774 | 28,781 |
| Total revenues | 7,011,383 | 5,335,750 | 4,230,045 |
| Costs and expenses: | |||
| Cost of goods sold | 1,595,558 | 1,127,246 | 768,771 |
| Research and development | 939,918 | 721,768 | 591,026 |
| Selling, general and administrative | 946,686 | 797,344 | 705,741 |
| Purchased in-process research and development | 0 | 10,851 | 0 |
| Total costs and expenses | 3,482,162 | 2,657,209 | 2,065,538 |
| Income from operations | 3,529,221 | 2,678,541 | 2,164,507 |
| Interest and other income, net | 42,397 | 59,401 | 109,823 |
| Interest expense | (69,662) | (65,244) | (63,181) |
| Income before provision for income taxes | 3,501,956 | 2,672,698 | 2,211,149 |
| Provision for income taxes | 876,364 | 702,363 | 635,355 |
| Net income | 2,625,592 | 1,970,335 | 1,575,794 |
| Net loss attributable to noncontrolling interest | 10,163 | 8,564 | 9,108 |
| Net income attributable to Gilead | 2,635,755 | 1,978,899 | 1,584,902 |
| Net income per share attributable to Gilead common stockholders-basic | 2.91 | 2.15 | 1.71 |
| Shares used in per share calculation-basic | 904,604 | 920,693 | 929,133 |
| Net income per share attributable to Gilead common stockholders-diluted | 2.82 | 2.06 | 1.64 |
| Shares used in per share calculation-diluted | 934,109 | 958,825 | 964,356 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2009 | |||
Statement Of Cash Flows Indirect | |||
Period Ending Dec 31, 2009 10-K (Filed: Mar 1, 2010) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2009 | Dec 31, 2008 | Dec 31, 2007 | |
| Operating activities: | |||
| Net income | $ 2,625,592 | 1,970,335 | 1,575,794 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation | 64,560 | 51,722 | 36,888 |
| Amortization | 148,384 | 103,888 | 64,472 |
| Purchased in-process research and development expense | 0 | 10,851 | 0 |
| Stock-based compensation expenses | 180,684 | 153,364 | 184,605 |
| Excess tax benefits from stock-based compensation | (80,186) | (191,939) | (76,276) |
| Tax benefits from employee stock plans | 88,368 | 209,519 | 110,678 |
| Deferred income taxes | (42,013) | (24,969) | 113,384 |
| Other non-cash transactions | 64,456 | (11,257) | (8,082) |
| Changes in operating assets and liabilities: | |||
| Accounts receivable, net | (356,462) | (257,161) | (138,034) |
| Inventories | (75,266) | (330,726) | (34,619) |
| Prepaid expenses and other assets | (65,667) | 9,719 | (252,489) |
| Accounts payable | 203,641 | 312,568 | (77,549) |
| Income taxes payable | 166,334 | (23,887) | 76,986 |
| Accrued liabilities | 109,026 | 136,276 | 80,087 |
| Deferred revenues | 48,603 | 25,081 | 13,237 |
| Net cash provided by operating activities | 3,080,054 | 2,143,384 | 1,669,082 |
| Investing activities: | |||
| Purchases of marketable securities | (2,614,046) | (3,273,112) | (3,502,119) |
| Proceeds from sales of marketable securities | 1,440,509 | 3,026,459 | 2,134,348 |
| Proceeds from maturities of marketable securities | 435,510 | 193,690 | 195,395 |
| Acquisitions, net of cash acquired | (1,247,816) | (10,851) | (46,443) |
| Purchases of non-marketable equity securities | 0 | 0 | (5,000) |
| Capital expenditures and other | (230,057) | (115,005) | (78,648) |
| Net cash used in investing activities | (2,215,900) | (178,819) | (1,302,467) |
| Financing activities: | |||
| Proceeds from issuances of common stock | 222,728 | 246,125 | 243,427 |
| Proceeds from credit facility | 400,000 | 0 | 0 |
| Repayment of credit facility | (400,000) | 0 | 0 |
| Repurchases of common stock | (998,495) | (1,969,582) | (487,543) |
| Extinguishment of long-term debt | (305,455) | 0 | 0 |
| Repayments of long-term debt and other obligations | (5,648) | (4,326) | (99,459) |
| Excess tax benefits from stock-based compensation | 80,186 | 191,939 | 76,276 |
| Distributions (to) from noncontrolling interest | (44,754) | 61,275 | 96,316 |
| Net cash used in financing activities | (1,051,438) | (1,474,569) | (170,983) |
| Effect of exchange rate changes on cash | 940 | 1,220 | (43,553) |
| Net change in cash and cash equivalents | (186,344) | 491,216 | 152,079 |
| Cash and cash equivalents at beginning of period | 1,459,302 | 968,086 | |
| Cash and cash equivalents at end of period | 1,272,958 | 1,459,302 | 968,086 |
| Supplemental disclosure of cash flow information: | |||
| Interest paid | 8,990 | 7,388 | 7,480 |
| Income taxes paid | 746,224 | 495,544 | 565,156 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
GILEAD SCIENCES, INC. | ||
Ticker: GILD Fiscal Year: 2009 | ||
Statement Of Financial Position Classified | ||
Period Ending Dec 31, 2009 10-K (Filed: Mar 1, 2010) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2009 | Dec 31, 2008 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $ 1,272,958 | 1,459,302 |
| Short-term marketable securities | 384,017 | 330,760 |
| Accounts receivable, net of allowances of $132,810 at December 31, 2009 and $90,694 at December 31, 2008 | 1,389,534 | 1,023,397 |
| Inventories | 1,051,771 | 927,868 |
| Deferred tax assets | 295,080 | 140,882 |
| Prepaid taxes | 274,196 | 198,318 |
| Prepaid expenses | 78,111 | 71,815 |
| Other current assets | 66,891 | 126,066 |
| Total current assets | 4,812,558 | 4,278,408 |
| Property, plant and equipment, net | 699,970 | 528,799 |
| Noncurrent portion of prepaid royalties | 226,250 | 257,208 |
| Noncurrent deferred tax assets | 101,498 | 226,728 |
| Long-term marketable securities | 2,247,871 | 1,449,577 |
| Intangible assets | 1,524,777 | 123,008 |
| Other noncurrent assets | 85,635 | 73,103 |
| Total assets | 9,698,559 | 6,936,831 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | 810,544 | 601,200 |
| Accrued government rebates | 248,660 | 176,939 |
| Accrued compensation and employee benefits | 132,481 | 103,840 |
| Income taxes payable | 167,623 | 44,757 |
| Other accrued liabilities | 384,015 | 245,662 |
| Deferred revenues | 122,721 | 42,963 |
| Current portion of other long-term obligations | 5,587 | 5,631 |
| Total current liabilities | 1,871,631 | 1,220,992 |
| Long-term deferred revenues | 43,026 | 74,181 |
| Convertible senior notes, net | 1,155,443 | 1,098,025 |
| Long-term income taxes payable | 87,383 | 56,588 |
| Other long-term obligations | 35,918 | 21,462 |
| Commitments and contingencies (Note 11) | ||
| Stockholders' equity: | ||
| Preferred stock, par value $0.001 per share; 5,000 shares authorized; none outstanding | 0 | 0 |
| Common stock, par value $0.001 per share; 2,800,000 shares authorized; 899,753 and 909,819 shares issued and outstanding at December 31, 2009 and 2008, respectively | 900 | 910 |
| Additional paid-in capital | 4,376,651 | 3,930,109 |
| Accumulated other comprehensive income (loss) | (5,758) | 41,240 |
| Retained earnings | 1,995,272 | 300,314 |
| Total Gilead stockholders' equity | 6,367,065 | 4,272,573 |
| Noncontrolling interest | 138,093 | 193,010 |
| Total stockholders' equity | 6,505,158 | 4,465,583 |
| Total liabilities and stockholders' equity | 9,698,559 | 6,936,831 |
| External Links | |
| GILEAD SCIENCES, INC. (GILD) Fiscal Year 2009 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |